Century Therapeutics (NASDAQ:IPSC) Releases Earnings Results, Beats Expectations By $0.02 EPS

Century Therapeutics (NASDAQ:IPSC) issued its earnings results on Wednesday. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02, Zacks reports. The company had revenue of $4.18 million for the quarter, compared to analysts’ expectations of $0.67 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%.

Century Therapeutics Trading Down 0.9 %

NASDAQ IPSC opened at $0.58 on Thursday. The firm has a market capitalization of $49.57 million, a price-to-earnings ratio of -0.32 and a beta of 1.75. The firm’s 50 day simple moving average is $0.76 and its 200 day simple moving average is $1.17. Century Therapeutics has a 1 year low of $0.55 and a 1 year high of $5.24.

Institutional Trading of Century Therapeutics

A hedge fund recently raised its stake in Century Therapeutics stock. Bank of America Corp DE boosted its stake in Century Therapeutics, Inc. (NASDAQ:IPSC) by 109.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,043 shares of the company’s stock after purchasing an additional 34,466 shares during the period. Bank of America Corp DE owned about 0.08% of Century Therapeutics worth $67,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on IPSC shares. Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler decreased their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.50.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.